CA2558126A1 - The treatment of inflammatory disorders and pain using beta-aminoalcohols - Google Patents

The treatment of inflammatory disorders and pain using beta-aminoalcohols Download PDF

Info

Publication number
CA2558126A1
CA2558126A1 CA002558126A CA2558126A CA2558126A1 CA 2558126 A1 CA2558126 A1 CA 2558126A1 CA 002558126 A CA002558126 A CA 002558126A CA 2558126 A CA2558126 A CA 2558126A CA 2558126 A1 CA2558126 A1 CA 2558126A1
Authority
CA
Canada
Prior art keywords
disease
condition
pain
use according
chronic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002558126A
Other languages
English (en)
French (fr)
Inventor
Andrew Douglas Baxter
John Brew
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sosei R&D Ltd
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0406016A external-priority patent/GB0406016D0/en
Priority claimed from GB0418556A external-priority patent/GB0418556D0/en
Priority claimed from GB0422880A external-priority patent/GB0422880D0/en
Application filed by Individual filed Critical Individual
Publication of CA2558126A1 publication Critical patent/CA2558126A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Hydrogenated Pyridines (AREA)
CA002558126A 2004-03-17 2005-03-17 The treatment of inflammatory disorders and pain using beta-aminoalcohols Abandoned CA2558126A1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
GB0406016A GB0406016D0 (en) 2004-03-17 2004-03-17 The treatment of inflammatory disorders
GB0406016.6 2004-03-17
GB0418556A GB0418556D0 (en) 2004-08-19 2004-08-19 The treatment of pain
GB0418556.7 2004-08-19
GB0422880A GB0422880D0 (en) 2004-10-14 2004-10-14 The treatment of inflammatory disorders
GB0422880.5 2004-10-14
PCT/GB2005/001031 WO2005089741A2 (en) 2004-03-17 2005-03-17 The treatment of inflammatory disorders and pain using beta-aminoalcohols

Publications (1)

Publication Number Publication Date
CA2558126A1 true CA2558126A1 (en) 2005-09-29

Family

ID=34962997

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002558126A Abandoned CA2558126A1 (en) 2004-03-17 2005-03-17 The treatment of inflammatory disorders and pain using beta-aminoalcohols

Country Status (6)

Country Link
US (1) US20070179181A1 (cg-RX-API-DMAC7.html)
EP (1) EP1725226A2 (cg-RX-API-DMAC7.html)
JP (1) JP2007529492A (cg-RX-API-DMAC7.html)
AU (1) AU2005224160A1 (cg-RX-API-DMAC7.html)
CA (1) CA2558126A1 (cg-RX-API-DMAC7.html)
WO (1) WO2005089741A2 (cg-RX-API-DMAC7.html)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1813285A4 (en) * 2004-11-19 2010-06-09 Kissei Pharmaceutical PROPHYLACTIC OR THERAPEUTIC AGENT AGAINST NEUROPATHIC PAIN
WO2006108424A2 (en) 2005-04-13 2006-10-19 Astion Pharma A/S Beta-2 adrenoceptor agonists for treating connective tissue diseases of the skin
GB0519274D0 (en) 2005-09-21 2005-11-02 Arakis Ltd The treatment of neurodegenerative diseases
GB0523964D0 (en) * 2005-11-24 2006-01-04 Arakis Ltd The treatment of ophthalmic diseases
GB0625270D0 (en) * 2006-12-19 2007-01-31 Univ Leicester Angiogenesis
JP2011509981A (ja) * 2008-01-18 2011-03-31 サントル ナショナル ドゥ ラ ルシェルシュ スィヤンティフィック(セーエヌエルエス) 神経障害性疼痛の治療に使用される化合物
FR2926464B1 (fr) * 2008-01-18 2012-01-20 Centre Nat Rech Scient Composes utilisables pour le traitement de douleurs neuropathiques
US20090264477A1 (en) * 2008-04-18 2009-10-22 Warsaw Orthopedic, Inc., An Indiana Corporation Beta adrenergic receptor agonists for treatment of pain and/or inflammation
WO2011112243A2 (en) * 2010-03-08 2011-09-15 The University Of Tennessee Research Foundation Beta -adrenergic receptor agonists and uses thereof
GB2484977A (en) * 2010-10-29 2012-05-02 Biocopea Ltd Treatment of a Th-1 mediated disease
EP2727587A1 (en) * 2012-10-30 2014-05-07 Pharnext Compositions, methods and uses for the treatment of diabetes and related conditions by controlling blood glucose level
CN104807909A (zh) * 2015-05-12 2015-07-29 广西壮族自治区梧州食品药品检验所 高精度测量猪尿中的克仑特罗含量的方法
CN104820047B (zh) * 2015-05-12 2016-06-29 广西壮族自治区梧州食品药品检验所 采用sle法同时分离猪尿中的莱克多巴胺、克仑特罗、沙丁胺醇的方法

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR6087M (cg-RX-API-DMAC7.html) * 1967-01-10 1968-06-04
US4086363A (en) * 1977-03-16 1978-04-25 Usv Pharmaceutical Corporation Treatment of asthma
US5668117A (en) * 1991-02-22 1997-09-16 Shapiro; Howard K. Methods of treating neurological diseases and etiologically related symptomology using carbonyl trapping agents in combination with previously known medicaments
US5264459A (en) * 1992-07-13 1993-11-23 Arch Development Corporation Use of β-adrenergic agonists to treat patients with demyelinating or autoimmune diseases
AUPN605795A0 (en) * 1995-10-19 1995-11-09 F.H. Faulding & Co. Limited Analgesic pharmaceutical composition
US6043283A (en) * 1996-09-20 2000-03-28 Baylor College Of Medicine Tyramine compounds and their neuronal effects
GB9804885D0 (en) * 1998-03-06 1998-04-29 Merck Sharp & Dohme Therapeutic combination
GB9804886D0 (en) * 1998-03-06 1998-04-29 Merck Sharp & Dohme Therapeutic combination
WO2001095903A1 (en) * 2000-06-15 2001-12-20 Respiratorius Ab 5-ht3 receptor antagonists for treatment of disorders involving airway constriction
AU2002211176A1 (en) * 2000-11-01 2002-05-15 Respiratorius Ab Composition comprising serotonin receptor antagonists, 5 ht-2 and 5 ht-3
AU2002212888A1 (en) * 2000-11-01 2002-05-15 Respiratorius Ab Composition comprising: serotonin receptor antagonists (5ht-2, 5ht-3) and agonist (5ht-4)
WO2002078670A1 (en) * 2001-03-02 2002-10-10 Neuron Therapeutics, Inc. Neuroprotectants formulations and methods
CN1646143A (zh) * 2002-04-19 2005-07-27 艾升发展公司 β-2肾上腺素受体兴奋剂与氨基糖的结合及其在治疗免疫功能紊乱方面的应用
WO2003092617A2 (en) * 2002-05-03 2003-11-13 Combinatorx, Incorporated Combinations for the treatment of inflammatory skin disorders
GB0210264D0 (en) * 2002-05-03 2002-06-12 Arakis Ltd The treatment of pain and migraine headache
US20040209850A1 (en) * 2003-04-15 2004-10-21 Theraquest Biosciences, Llc Methods of treating pain and compositions for use therefor
PT1651270E (pt) * 2003-07-29 2007-04-30 Boehringer Ingelheim Int Medicamentos para inalação compreendendo betamiméticos e um anticolinérgico
US7462618B2 (en) * 2003-08-27 2008-12-09 Sun Health Research Institute Treatment of inflammatory autoimmune diseases with alpha-adrenergic antagonists and beta-adrenergic agonists
CA2544611A1 (en) * 2003-10-09 2005-04-21 Inverseon, Inc. Method of treating airway diseases with beta-adrenergic inverse agonists
AU2004285329A1 (en) * 2003-10-21 2005-05-12 Arakis Ltd. The use of ifenprodil in the treatment of pain

Also Published As

Publication number Publication date
JP2007529492A (ja) 2007-10-25
WO2005089741A2 (en) 2005-09-29
WO2005089741A3 (en) 2006-03-23
AU2005224160A1 (en) 2005-09-29
EP1725226A2 (en) 2006-11-29
US20070179181A1 (en) 2007-08-02

Similar Documents

Publication Publication Date Title
US20080096971A1 (en) Treatment of Inflammatory Disorders and Pain
US20070179181A1 (en) Treatment of inflammatory disorders and pain using beta-aminoalcohols
US20100076068A1 (en) Aminoalcohol Derivatives and Their Therapeutic Use
US20100016357A1 (en) Use of Beta-Aminoalcohols for the Treatment of Inflammatory Disorders and Pain
AU2007222217B2 (en) The use of bupropion metabolites for the treatment of inflammatory disorders
US8188150B2 (en) Use of beta-aminoalcohols in the treatment of inflammatory disorders and pain
ZA200702002B (en) The treatment of inflammatory disorders and pain
US20080306162A1 (en) Treatment of Inflammatory Disorders and Pain
HK1120216B (en) The use of bupropion metabolites for the treatment of inflammatory disorders
EP1940376A2 (en) Use of neboglamine in the treatment of toxicodependency

Legal Events

Date Code Title Description
FZDE Discontinued